替吉奥联合顺铂治疗晚期肺鳞癌的临床研究  

Clinical research of tegafur gimeracil oteracil potassium capsule combined with cisplatin in the treatment of advanced lung squamous carcinoma

作　　者：程燕[1] 周恒根[1] 刘兰芳[1] 倪敬中[1] 李亚莉[1] 

机构地区：[1]江苏省邳州市人民医院肿瘤内科,221399

出　　处：《中国实用医药》2015年第10期42-43,共2页China Practical Medicine

摘　　要：目的分析探讨替吉奥联合顺铂治疗晚期肺鳞癌的临床疗效。方法回顾性分析32例晚期肺鳞癌患者的临床记录资料,所有患者均给予替吉奥联合顺铂治疗,观察治疗效果。结果 32例患者中,无完全缓解(CR)患者,部分缓解(PR)10例(31.25%),稳定(SD)15例(46.88%),进展(PD)7例(21.88%),疾病控制率为78.13%。32例患者1年及2年生存率分别为53.13%(17/32)、15.63%(5/32)。主要毒副反应为骨髓抑制、轻度胃肠道症状及脱发。结论替吉奥联合顺铂治疗晚期肺鳞癌具有较好的疗效,毒副反应轻微,患者均可耐受。Objective To analyze and investigate the clinical effect of tegafur gimeracil oteracil potassium capsule combined with cisplatin in the treatment of advanced lung squamous carcinoma.Methods A retrospective analysis was made on the clinical data of 32 patients with advanced lung squamous carcinoma. All patients received treatment by tegafur gimeracil oteracil potassium capsule combined with cisplatin, and their curative effects were observed.Results Among the 32 patients, there were no complete remission case, 10 partial remission cases （31.25%）, 15 cases with stable disease （46.88%）, and 7 cases with progressive disease （21.88%）. The disease control rate was 78.13%. The 1-year and 2-year survival rates of the 32 cases were respectively 53.13% （17/32） and 15.63% （5/32）. The main toxic and adverse effects included myelosuppression, mild gastrointestinal symptoms, and baldness.Conclusion The combination of tegafur gimeracil oteracil potassium capsule and cisplatin has good effect in treating advanced lung squamous carcinoma with mild toxic and side reactions that can be tolerated by patients.

关 键 词：替吉奥 顺铂 晚期肺鳞癌 

分 类 号：R734.2[医药卫生—肿瘤]